The calprotectin testing market is capturing a valuation of US$ 201.1 billion in 2023 and is predicted to reach US$ 360.2 billion by 2033. The market is registering a CAGR of 6% during the forecast period.
The market is driven by various factors, including:
Lack of Awareness and Low Standardized Product Limit the Market Growth
Various factors restrain market growth are:
| Attributes | Details |
|---|---|
| Market CAGR (2023 to 2033) | 6% |
| Market Valuation (2023) | US$ 201.1 billion |
| Market Valuation (2033) | US$ 360.2 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market experienced steady growth between 2018 and 2022. The market was valued at US$ 190.5 billion in 2022, with a CAGR of 5.3% between 2018 and 2022. A surge in chronic patients, increasing demand for non-invasive diagnostic tools, and growing advanced technology have driven the market size.
The market has faced various challenges, such as limited awareness, low-quality tools, and high competition. The various end-use sectors, such as hospitals, specialty clinics, and others, continuously grow the market revenue during the forecast period. Healthcare manufacturers are developing advanced tools to detect and monitor patients' chronic conditions.
Based on test kits, calprotectin ELISA test kits are estimated to dominate the global market by securing a share of 90.46% during the forecast period. The laboratory's adoption of calprotectin ELISA test kits is increasing to detect and qualify biological samples. These kits help measure the calprotectin level, advancing the market growth.
The demand for calprotectin ELISA test kits is rising due to their ability to collect multiple samples and ease to use with high sensitivity. The growing popularity of these devices among healthcare professionals is fueling the market size. The manufacturers are distributors offering multiple kits with their respective uses, and benefits are advancing the market opportunities.
Based on indication, irritable bowel syndrome is anticipated to lead the global market by registering a share of 79% during the forecast period. Irritable bowel syndrome is a prime indication segment that affects the large intestine. The rising prevalence of irritable bowel syndrome surges the demand for calprotectin testing.
Principal Consultant
| Countries | Projected Value (2023 to 2033) |
|---|---|
| United States | 25.7% |
| Germany | 3% |
| Japan | 3.1% |
| Australia | 5.6% |
| China | 7.8% |
| India | 8.7% |
| United Kingdom | 6.2% |
The United States is estimated to dominate the global market by securing a share of 25.7% during the forecast period. The increasingly advanced testing technology and growing patient awareness fuel the country's market size. The growth in gastrointestinal disorders and chronic diseases is increasing the adoption of calprotectin testing in the healthcare sector.
Healthcare manufacturers are developing advanced testing equipment to monitor patients' diseases and enhance the performance of checkups. These manufacturers offer a variety of testing tools to monitor the diagnostic condition of patients. Additionally, provide better services expanding the United States calprotectin testing market.
Germany is one of the significant countries in the global market that secure a share of 3% during the forecast period. Various factors are driving the German market are:
Japan is one of the significant countries in the global market, capturing a share of 3.1% during the forecast period. The rising prevalence of inflammatory bowel disease is fueling the market growth in Japan. For Instance, around 2,00,000 people have been affected by inflammatory bowel disease recently.
The aging population and chronic patients are increasing the demand for calprotectin testing in Japan. The surging demand for diagnostic tests among patients is increasing the adoption of these testing tools. The manufacturers in Japan are investing in research and development activities to upsurge the medical field. Several Japanese companies are improving testing devices to provide accuracy in testing.
The increasing aging population and strong research activities are innovating unique products that satisfy healthcare providers' and patients' requirements. These factors are contributing to uplifting Japan's calprotectin testing market.
With the following steps, the manufacturers can expand the global market are:
These are a few steps on which the manufacturers can expand the global market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Several key players highly influence the market. The key players are developing unique and advanced testing devices to detect and monitor patients' chronic diseases. They are investing in research and development activities and offer better solutions with advanced technologies.
These players are fueling the healthcare sector by increasing their services as per consumers' needs. The players are adopting various marketing tactics to enhance the global market size. These marketing strategies are collaborations, acquisitions, mergers, partnerships, agreements, and product launches.
Other Essential Players in the Market are:
Recent Development in the Global Market are:
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ billion for Value |
| Key Countries Covered | The United States, The United Kingdom, Japan, India, China, Australia, Germany |
| Key Segments Covered | Test Kit, Sample, Indication, End Use, Region |
| Key Companies Profiled | Actim Oy; Calpro AS; BÜHLMANN Laboratories AG; EagleBio; CerTest Biotec S.L.; EUROIMMUN Medizinische Labordiagnostika AG; Boditech Med Inc.; Biohit Oyj; American Laboratory Products Company, Ltd.; DIAsource ImmunoAssays S.A; R-Biopharm AG.; Abbexa; AccuBio Tech Co., Ltd.; Screen Italia Srl.; Hangzhou Biotest Biotech Co., Ltd; Thermo Fisher Scientific; Epitope Diagnostics, Inc.; Elabscience Biotechnology Inc; Vitassay Healthcare, S.L.U.; Beckman Coulter Inc.; DiaSorin |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The 2023 market value is US$ 201.1 billion.
Until 2033, the market will rise at a 6% CAGR.
By 2033, the market will total US$ 360.2 billion.
Rising gastrointestinal disorder diagnoses propel market growth.
North America will be a highly lucrative market.
1. Executive Summary | Calprotectin Testing Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Kits
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Test Kits, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Kits, 2023 to 2033
5.3.1. Calprotectin ELISA
5.3.2. Calprotectin Rapid
5.4. Y-o-Y Growth Trend Analysis By Test Kits, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Test Kits, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sample
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Sample, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Sample, 2023 to 2033
6.3.1. Stool
6.3.2. Plasma
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By Sample, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Sample, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Indication , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication , 2023 to 2033
7.3.1. Irritable Bowel Syndrome (IBS)
7.3.2. Ulcerative Colitis
7.3.3. Crohn's Disease
7.3.4. Colorectal Cancer
7.4. Y-o-Y Growth Trend Analysis By Indication , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Indication , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2023 to 2033
8.3.1. Hospitals
8.3.2. Diagnostic Laboratories
8.3.3. Specialty Clinics
8.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. MEA
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. United States of America
10.2.1.2. Canada
10.2.2. By Test Kits
10.2.3. By Sample
10.2.4. By Indication
10.2.5. By End-User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Test Kits
10.3.3. By Sample
10.3.4. By Indication
10.3.5. By End-User
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Test Kits
11.2.3. By Sample
11.2.4. By Indication
11.2.5. By End-User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Test Kits
11.3.3. By Sample
11.3.4. By Indication
11.3.5. By End-User
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United Kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Test Kits
12.2.3. By Sample
12.2.4. By Indication
12.2.5. By End-User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Test Kits
12.3.3. By Sample
12.3.4. By Indication
12.3.5. By End-User
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Test Kits
13.2.3. By Sample
13.2.4. By Indication
13.2.5. By End-User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Test Kits
13.3.3. By Sample
13.3.4. By Indication
13.3.5. By End-User
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Test Kits
14.2.3. By Sample
14.2.4. By Indication
14.2.5. By End-User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Test Kits
14.3.3. By Sample
14.3.4. By Indication
14.3.5. By End-User
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Test Kits
15.2.3. By Sample
15.2.4. By Indication
15.2.5. By End-User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Test Kits
15.3.3. By Sample
15.3.4. By Indication
15.3.5. By End-User
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Test Kits
16.2.3. By Sample
16.2.4. By Indication
16.2.5. By End-User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Test Kits
16.3.3. By Sample
16.3.4. By Indication
16.3.5. By End-User
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. United States of America
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Test Kits
17.1.2.2. By Sample
17.1.2.3. By Indication
17.1.2.4. By End-User
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Test Kits
17.2.2.2. By Sample
17.2.2.3. By Indication
17.2.2.4. By End-User
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Test Kits
17.3.2.2. By Sample
17.3.2.3. By Indication
17.3.2.4. By End-User
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Test Kits
17.4.2.2. By Sample
17.4.2.3. By Indication
17.4.2.4. By End-User
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Test Kits
17.5.2.2. By Sample
17.5.2.3. By Indication
17.5.2.4. By End-User
17.6. United Kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Test Kits
17.6.2.2. By Sample
17.6.2.3. By Indication
17.6.2.4. By End-User
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Test Kits
17.7.2.2. By Sample
17.7.2.3. By Indication
17.7.2.4. By End-User
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Test Kits
17.8.2.2. By Sample
17.8.2.3. By Indication
17.8.2.4. By End-User
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Test Kits
17.9.2.2. By Sample
17.9.2.3. By Indication
17.9.2.4. By End-User
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Test Kits
17.10.2.2. By Sample
17.10.2.3. By Indication
17.10.2.4. By End-User
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Test Kits
17.11.2.2. By Sample
17.11.2.3. By Indication
17.11.2.4. By End-User
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Test Kits
17.12.2.2. By Sample
17.12.2.3. By Indication
17.12.2.4. By End-User
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Test Kits
17.13.2.2. By Sample
17.13.2.3. By Indication
17.13.2.4. By End-User
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Test Kits
17.14.2.2. By Sample
17.14.2.3. By Indication
17.14.2.4. By End-User
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Test Kits
17.15.2.2. By Sample
17.15.2.3. By Indication
17.15.2.4. By End-User
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Test Kits
17.16.2.2. By Sample
17.16.2.3. By Indication
17.16.2.4. By End-User
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Test Kits
17.17.2.2. By Sample
17.17.2.3. By Indication
17.17.2.4. By End-User
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Test Kits
17.18.2.2. By Sample
17.18.2.3. By Indication
17.18.2.4. By End-User
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Test Kits
17.19.2.2. By Sample
17.19.2.3. By Indication
17.19.2.4. By End-User
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Test Kits
17.20.2.2. By Sample
17.20.2.3. By Indication
17.20.2.4. By End-User
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Test Kits
17.21.2.2. By Sample
17.21.2.3. By Indication
17.21.2.4. By End-User
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Test Kits
18.3.3. By Sample
18.3.4. By Indication
18.3.5. By End-User
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Actim Oy
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Calpro AS
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. BÜHLMANN Laboratories AG
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. EagleBio
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. CerTest Biotec S.L.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. EUROIMMUN Medizinische Labordiagnostika AG
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Boditech Med Inc.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Biohit Oyj
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. American Laboratory Products Company, Ltd.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. DIAsource ImmunoAssays S.A
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. R-Biopharm AG.
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Abbexa
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.13. AccuBio Tech Co., Ltd.
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
19.1.14. Screen Italia Srl.
19.1.14.1. Overview
19.1.14.2. Product Portfolio
19.1.14.3. Profitability by Market Segments
19.1.14.4. Sales Footprint
19.1.14.5. Strategy Overview
19.1.14.5.1. Marketing Strategy
19.1.15. Hangzhou Biotest Biotech Co., Ltd
19.1.15.1. Overview
19.1.15.2. Product Portfolio
19.1.15.3. Profitability by Market Segments
19.1.15.4. Sales Footprint
19.1.15.5. Strategy Overview
19.1.15.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Calprotectin Testing Market
